Mayo Clinic researchers develop a tissue-derived bioactive gel to stop bleeding, aid in vascular healing

PHOENIX, AZ --Researchers at Mayo Clinic are studying the effects of a tissue-derived bioactive gel they developed to improve endovascular embolization - a minimally invasive procedure used to treat bleeding blood vessels and aneurysms. The results of their latest preclinical study are published in the journal Advanced Materials. Endovascular embolization involves a pinhole puncture in [...]
Source: Mayo Clinic Research News - Category: Research Source Type: news

Related Links:

AbstractObjectivesTo analyze the association between systemic inflammatory burden of cardiovascular disease (CVD) risk and periodontitis in adolescents, including mediating pathways triggered by their common risk factors.Materials and methodsUsing a population-based sample study (n = 405) of Brazilian adolescents (17 –18 years old), direct and mediation pathways triggered by “Socioeconomic Status,” “Adiposity,” Smoking, and “Blood Pressure” were modelled for the association between the “Systemic Circulating Inflammatory Burden of CVD Risk” (IL-1β, IL-6, IL-8, TNF-&...
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
ConclusionsSurgical and non-surgical debridement for the treatment of peri-implantitis present similar clinical outcomes. Bone levels were better improved in ST than NST for sites with higher initial bone loss.Clinical relevanceThe treatment of peri-implantitis is still a challenge in clinical practice, since less than half of affected implants achieve health after surgical or non-surgical debridement. Considering the lack of clinically relevant differences between these two treatments, non-surgical debridement should be considered the first therapeutic choice for peri-implantitis, mainly mild to moderate cases.
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
New data from MR CLEAN-MED show that aspirin and heparin, alone or in combination, double the risk for symptomatic intracranial hemorrhage when given during endovascular therapy (EVT) for ischemic stroke.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Can J Anaesth. 2021 Sep 14. doi: 10.1007/s12630-021-02100-4. Online ahead of print.ABSTRACTPURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes.METHODS: This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical pati...
Source: Canadian Journal of Anaesthesia - Category: Anesthesiology Authors: Source Type: research
CONCLUSION: Management recommendations for hemorrhage associated with DOAC use vary, depending on the class of the culprit agent (direct thrombin inhibitor vs. FXa inhibitor), the clinical status of the patient (mild/ moderate vs. severe/life-threatening), and capabilities of the institution. Specific reversal agents (i.e., idarucizumab and andexanet alfa) can be used if available, while prothrombin complex concentrates, fresh frozen plasma and/ or tranexamic acid can also be employed as nonspecific replacement agents in the management of DOAC-related bleeding diathesis.PMID:34521332 | DOI:10.2174/1871525719666210914110750
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Authors: Source Type: research
This study investigated the effectiveness of four-factor prothrombin complex concentrate in treating trauma-related hemorrhage with rivaroxaban-anticoagulation in a pig polytrauma model. This study also tested the hypothesis that the combined use of a low dose of prothrombin complex concentrate plus tranexamic acid and fibrinogen concentrate could improve its subtherapeutic effects.MethodsTrauma (blunt liver injury and bilateral femur fractures) was induced in 48 anesthetized male pigs after 30 min of rivaroxaban infusion (1 mg/kg). Animals in the first part of the study received prothrombin complex concentrate (12.5, 25, ...
Source: Anesthesiology - Category: Anesthesiology Source Type: research
“What are the issues facing clinicians who manage bleeding patients receiving direct oral anticoagulants?”
Source: Anesthesiology - Category: Anesthesiology Source Type: research
AbstractThe improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically the population of the LVAD-supported patients and the probability of those patients to present to the emergency department with expected and non-expected device-related and patient –device interaction complications. The ageing of the LVAD-supported patients, mainly those supported with the ‘destination therapy’ indication, increases the risk for those patients to suffer from other co-morbidities common in the older population. In this second part of the trilogy on the ma nag...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: ESC and HFA Paper Source Type: research
This study assessed the effectiveness and safety of proton pump inhibitors (PPIs) compared to histamine type 2 receptor antagonists (H2RAs) for prevention of CIGB in mechanically ventilated patients.DesignThis is a retrospective, single-center, pharmacoepidemiologic study.SettingThis study was carried out in six intensive care units (ICUs).PatientsCritically ill adults admitted between 9/1/14 and 9/1/19 who received PPIs or H2RAs within 24  h of intubation and for ≥48 h were included in this study.InterventionPPIs or H2RAs for stress ulcer prophylaxis.Measurements and Main ResultsPrimary outcomes were CIGB occ...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
AbstractGastric antral vascular ectasia (GAVE) is an uncommon clinical entity leading to recurrent gastrointestinal bleeding. There is no consensus regarding treatment of GAVE. Endoscopic therapy is the preferred treatment option, but has a fairly high recurrence rate. Surgical resection can completely resolve GAVE, but is invasive with a relatively high risk of postoperative complications. Recently, the role of pharmacotherapy for GAVE has been recognized. However, the evidence is limited to scattered case reports or small case series. This review comprehensively summarizes the efficacy and side effects of drugs commonly ...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Bleeding | Research | Study